Document:

Exhibit 10.1

 

Eagle
Pharmaceuticals, Inc.

Amended
and Restated Severance Benefit Plan

 

Section
1.             Introduction.

 

The Eagle Pharmaceuticals,
Inc. Severance Benefit Plan (the “Plan”) is hereby established effective as of December 10, 2019 (the
“Effective Date”). The purpose of the Plan is to provide for the payment of severance and/or change in
control benefits to eligible employees of Eagle Pharmaceuticals, Inc. (the “Company”). This Plan document
also is the Summary Plan Description for the Plan.

 

For purposes of the Plan,
the following terms are defined as follows:

 

(a)          
“Affiliate” means any corporation (other than the Company) in an “unbroken chain
of corporations” beginning with the Company, if each of the corporations other than the last corporation in the unbroken
chain owns stock possessing 50% or more of the total combined voting power of all classes of stock in one of the other corporations
in such chain.

 

(b)          
“Base Salary” means base pay (excluding incentive pay, premium pay, draws, commissions,
overtime, bonuses and other forms of variable compensation) as in effect prior to any reduction that would give rise to an employee’s
right to a resignation for Good Reason (if applicable).

 

(c)          
“Cause” means, with respect to a particular employee, the meaning ascribed to such
term in any written employment agreement, offer letter or similar agreement between such employee and the Company defining such
term, and, in the absence of such agreement, has the meaning ascribed to such term in the Equity Plan. The determination whether
a termination is for Cause shall be made by the Plan Administrator in its sole and exclusive judgment and discretion.

 

(d)          
“Change in Control” has the meaning ascribed to such term in the Equity Plan.

 

(e)          
“Change in Control Period” means the period commencing three months prior to the Closing
of a Change in Control and ending 12 months following the Closing of a Change in Control.

 

(f)          
“Closing” means the initial closing of the Change in Control as defined in the definitive
agreement executed in connection with the Change in Control. In the case of a series of transactions constituting a Change in Control,
“Closing” means the first closing that satisfies the threshold of the definition for a Change in Control.

 

(g)          
“Code” means the Internal Revenue Code of 1986, as amended, including any applicable
regulations and guidance thereunder.

 

(h)          
“Committee” means the Board of Directors or the Compensation Committee of the Board
of Directors of the Company.

 

     

     

    

 

(i)          
“Company” means Eagle Pharmaceuticals, Inc. or, following a Change in Control, the
surviving entity resulting from such event.

 

(j)          
“Covered Termination” means, with respect to an employee, a termination of employment
that is due to (1) a termination by the Company without Cause (and other than as a result of the employee’s death or Disability)
or (2) the employee’s resignation for Good Reason.

 

(k)         “Death
or Disability Termination” means, with respect to an employee, a termination of employment that is due to the employee’s
death or Disability.

 

(l)          “Disability”
means an employee satisfies (i) the requirements for benefits under the Company’s long-term disability plan, as determined
by the third-party long-term disability insurance carrier or (ii) if the Company does not have a long-term disability plan, the
requirements for Social Security disability benefits, as determined by the Social Security Administration.

 

(m)         “Eligible
Employee” means an employee of the Company that meets the requirements to be eligible to receive Plan benefits as
set forth in Section 2.

 

(n)         
“Equity Plan” means the Eagle Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as
amended from time to time.

 

(o)        “Good
Reason” for an employee’s resignation means, notwithstanding the meaning ascribed to such term (or similar
term) in any written agreement between such employee and the Company, that one or more of the following are undertaken by the
Company (or successor to the Company, if applicable) without such employee’s express written consent:

 

(i) a material
reduction in such employee’s annual base salary, which employee agrees is a reduction of at least 10% of such employee’s
base salary (unless pursuant to a salary reduction program applicable generally to the Company’s similarly situated employees);

 

(ii) a material
diminution in such employee’s authority, duties, or responsibilities, including, solely with respect to the Company’s
Chief Executive Officer, a requirement that such employee report to a corporate officer or employee instead of reporting directly
to the board of directors of the Company (or, if applicable, the successor the Company or similar governing body if such successor
is an entity other than a corporation);

 

(iii) a relocation
of such employee’s principal place of employment with the Company (or successor to the Company, if applicable) to a place
that increases such employee’s one-way commute by more than 50 miles as compared to such employee’s then-current principal
place of employment immediately prior to such relocation (excluding regular travel in the ordinary course of business); provided
that if such employee’s principal place of employment is the employee’s personal residence, this clause (iii) shall
not apply; or

 

    	 	2.	 

     

    

 

(iv) a material
breach by the Company of any provisions of this Plan or any other material written agreement between such employee and the Company
concerning the terms and conditions of such employee’s employment with the Company.

 

In addition,
in each case (i) through (iv) described above, in order for the employee’s resignation to be deemed to have been for Good
Reason, the employee must first give the Company written notice of the action or omission giving rise to “Good Reason”
within 30 days after the first occurrence thereof; the Company must fail to reasonably cure such action or omission within
30 days after receipt of such notice (the “Cure Period”), and the employee’s resignation must
be effective not later than 30 days after the expiration of such Cure Period.

 

(p)         
“Participation Agreement” means an agreement between an employee and the Company in
substantially the form of Appendix A
attached hereto, and which may include such other terms as the Committee deems necessary or advisable in the administration of
the Plan.

 

(q)         
“Plan Administrator” means the Committee prior to the Closing and the Representative
upon and following the Closing, as applicable.

 

(r)          
“Representative” means one or more members of the Committee or other persons or entities
designated by the Committee prior to or in connection with a Change in Control that will have authority to administer and interpret
the Plan upon and following the Closing as provided in Section 8(a).

 

(s)          
“Section 409A” means Section 409A of the Code and any state law of similar effect.

 

Section
2.            
Eligibility for Benefits.

 

(a)            Eligible
Employee. An individual is eligible to receive benefits under the Plan if (i) the Committee (or its authorized designee) has
designated such individual as an employee of the Company who is eligible to participate in the Plan by providing such person with
an Participation Agreement; (ii) such employee has signed and returned such Participation Agreement to the Company within the
time period required therein; and (iii) such employee meets the other Plan eligibility requirements set forth in this Section
2. The determination of whether an individual is an Eligible Employee shall be made by the Plan Administrator, in its sole discretion,
and such determination shall be binding and conclusive on all persons.

 

(b)            Release Requirement. Except as otherwise provided in an individual Participation Agreement, in order to
be eligible to receive benefits under the Plan, the employee also must execute a general waiver and release, in such a form as
provided by the Company (the “Release”), within the applicable time period set forth therein, and such
Release must become effective in accordance with its terms, which must occur in no event more than 60 days following the date of
the applicable Covered Termination or Death or Disability Termination.

 

    	 	3.	 

     

    

 

(c)           Plan
Benefits Supersede Prior Benefits. For each Eligible Employee, this Plan shall supersede the Company’s Officer Severance
Benefit Plan effective August 4, 2015 and except as explicitly stated otherwise in this Plan or an individual Participation Agreement,
any change in control or severance benefit plan, policy or practice previously maintained by the Company with respect to an Eligible
Employee and any change in control or severance benefits in any individually negotiated employment contract or other agreement
between the Company and an Eligible Employee, including but not limited to any individual equity award vesting acceleration benefit
letter agreement between the Company and such Eligible Employee. Notwithstanding the foregoing, the Eligible Employee’s
outstanding equity awards covering Company common stock shall remain subject to the terms the Equity Plan or other applicable
equity plan under which such awards were granted that may apply upon a Change in Control and/or termination of such employee’s
service and no provision of this Plan shall be construed as to limit the actions that may be taken, or to violate the terms, thereunder.

 

(d)            Exceptions to Severance Benefit Entitlement. Except as otherwise provided in an Individual Participation
Agreement, an employee who otherwise is an Eligible Employee will not receive severance benefits under the Plan in the following
circumstances, as determined by the Plan Administrator in its sole discretion:

 

(1)          The
employee is terminated by the Company for any reason or voluntarily terminates employment with the Company in any manner, and
in either case, such termination does not constitute a Covered Termination or a Death or Disability Termination. Voluntary terminations
include, but are not limited to, resignation, retirement or failure to return from a leave of absence on the scheduled date.

 

(2)          The employee voluntarily terminates employment with the Company in order to accept employment with another entity
that is wholly or partly owned (directly or indirectly) by the Company or an Affiliate.

 

(3)          The
employee is offered an identical or substantially equivalent or comparable position with the Company or an Affiliate. For purposes
of the foregoing, a “substantially equivalent or comparable position” is one that provides the employee substantially
the same level of responsibility and compensation and would not give rise to the employee’s right to a resignation for Good
Reason.

 

(4)          The
employee is offered immediate reemployment by a successor to the Company or an Affiliate or by a purchaser of the Company’s
assets, as the case may be, following a Change in Control and the terms of such reemployment would not give rise to the employee’s
right to a resignation for Good Reason. For purposes of the foregoing, “immediate reemployment” means that the employee’s
employment with the successor to the Company or an Affiliate or the purchaser of its assets, as the case may be, results in uninterrupted
employment such that the employee does not incur a lapse in pay or benefits as a result of the change in ownership of the Company
or the sale of its assets. For the avoidance of doubt, an employee who becomes immediately reemployed as described in this Section
2(d)(4) by a successor to the Company or an Affiliate or by a purchaser of the Company’s assets, as the case may be, following
a Change in Control shall continue to be an Eligible Employee following the date of such reemployment.

 

    	 	4.	 

     

    

 

(5)             The
employee is rehired by the Company or an Affiliate and recommences employment prior to the date severance benefits under the Plan
are scheduled to commence.

 

(e)           Termination
or Reduction of Severance Benefits. An Eligible Employee’s right to receive severance benefits under this Plan shall
terminate immediately if, at any time prior to or during the period for which the Eligible Employee is receiving severance benefits
under the Plan, the Eligible Employee, without the prior written approval of the Plan Administrator willfully breaches any material
statutory, common law, or contractual obligation to the Company or an Affiliate (including, without limitation, the contractual
obligations set forth in any confidentiality, non-disclosure and developments agreement, non-competition, non-solicitation, or
similar type agreement between the Eligible Employee and the Company, as applicable).

 

Section
3.             Amount
of Benefits.

 

(a)            Benefits
in Participation Agreement. Benefits under the Plan shall be provided to an Eligible Employee as set forth in the Participation
Agreement.

 

(b)            Additional
Benefits. Notwithstanding the foregoing, the Plan Adminsitrator may, in its sole discretion, provide benefits to individuals
who are not Eligible Employees (“Non-Eligible Employees”) chosen by the Plan Administrator, in its sole
discretion, and the provision of any such benefits to a Non-Eligible Employee shall in no way obligate the Company to provide
such benefits to any other individual, even if similarly situated. If benefits under the Plan are provided to a Non-Eligible Employee,
references in the Plan to “Eligible Employee” (and similar references) shall be deemed to refer to such Non-Eligible
Employee.

 

(c)            Certain
Reductions. In addition to Section 2(e) above, the Company, in its sole discretion, shall have the authority to reduce an
Eligible Employee’s severance benefits, in whole or in part, by any other severance benefits, pay and benefits provided
during a period following written notice of a business closing or mass layoff, pay and benefits in lieu of such notice, or other
similar benefits payable to the Eligible Employee by the Company or an Affiliate that become payable in connection with the Eligible
Employee’s termination of employment pursuant to (i) any applicable legal requirement, including, without limitation, the
Worker Adjustment and Retraining Notification Act or any other similar state law or (ii) any Company policy or practice providing
for the Eligible Employee to remain on the payroll for a limited period of time after being given notice of the termination of
the Eligible Employee’s employment, and the Plan Administrator shall so construe and implement the terms of the Plan. Any
such reductions that the Company determines to make pursuant to this Section 3(c) shall be made such that any severance benefit
under the Plan shall be reduced solely by any similar type of benefit under such legal requirement, agreement, policy or practice
(i.e., any cash severance benefits under the Plan shall be reduced solely by any cash payments or severance benefits under
such legal requirement, agreement, policy or practice). The Company’s decision to apply such reductions to the severance
benefits of one Eligible Employee and the amount of such reductions shall in no way obligate the Company to apply the same reductions
in the same amounts to the severance benefits of any other Eligible Employee. In the Company’s sole discretion, such reductions
may be applied on a retroactive basis, with severance benefits previously paid being re-characterized as payments pursuant to
the Company’s statutory obligation.

 

    	 	5.	 

     

    

 

Section
4.             Return
of Company Property.

 

An Eligible Employee
will not be entitled to any severance benefit under the Plan unless and until the Eligible Employee returns all Company Property
and satisfies any outstanding indebtedness such Employee has to the Company in full. For this purpose, “Company Property”
means all Company paper and electronic documents (and all copies thereof) and other Company property which the Eligible Employee
had in his or her possession or control at any time, including, but not limited to, Company files, notes, drawings, records, plans,
forecasts, reports, studies, analyses, proposals, agreements, financial information, research and development information, sales
and marketing information, operational and personnel information, specifications, code, software, databases, computer-recorded
information, tangible property and equipment (including, but not limited to, computers, facsimile machines, mobile telephones,
servers), credit cards, entry cards, identification badges and keys; and any materials of any kind which contain or embody any
proprietary or confidential information of the Company (and all reproductions thereof in whole or in part).

 

Section
5.             Time of Payment and Form of Benefits.

 

The Company reserves
the right in the Participation Agreement to specify whether payments under the Plan will be paid in a single sum, in installments,
or in any other form and to determine the timing of such payments. All such payments under the Plan will be subject to applicable
withholding for federal, state, foreign, provincial and local taxes. All benefits provided under the Plan are intended to satisfy
the requirements for an exemption from application of Section 409A to the maximum extent that an exemption is available and any
ambiguities herein shall be interpreted accordingly; provided, however, that to the extent such an exemption is not available,
the benefits provided under the Plan are intended to comply with the requirements of Section 409A to the extent necessary to avoid
adverse personal tax consequences and any ambiguities herein shall be interpreted accordingly.

 

Notwithstanding anything
to the contrary set forth herein, any payments and benefits provided under the Plan that constitute “deferred compensation”
within the meaning of Section 409A shall not commence in connection with an Eligible Employee’s termination of employment
unless and until the Eligible Employee has also incurred a “separation from service,” as such term is defined in Treasury
Regulations Section 1.409A-1(h) (“Separation from Service”), unless the Company reasonably determines
that such amounts may be provided to the Eligible Employee without causing the Eligible Employee to incur the adverse personal
tax consequences under Section 409A.

 

    	 	6.	 

     

    

 

It is intended that (i)
each installment of any benefits payable under the Plan to an Eligible Employee be regarded as a separate “payment”
for purposes of Treasury Regulations Section 1.409A-2(b)(2)(i), (ii) all payments of any such benefits under the Plan satisfy,
to the greatest extent possible, the exemptions from the application of Section 409A provided under Treasury Regulations Sections
1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9)(iii), and (iii) any such benefits consisting of COBRA premiums also satisfy,
to the greatest extent possible, the exemption from the application of Section 409A provided under Treasury Regulations Section
1.409A-1(b)(9)(v). However, if the Company determines that any severance benefits payable under the Plan constitute “deferred
compensation” under Section 409A and the Eligible Employee is a “specified employee” of the Company, as such
term is defined in Section 409A(a)(2)(B)(i), then, solely to the extent necessary to avoid the imposition of the adverse personal
tax consequences under Section 409A, (A) the timing of such severance benefit payments shall be delayed until the earlier of (1)
the date that is six months and one day after the Eligible Employee’s Separation from Service and (2) the date of the Eligible
Employee’s death (such applicable date, the “Delayed Initial Payment Date”), and (B) the Company
shall (1) pay the Eligible Employee a lump sum amount equal to the sum of the severance benefit payments that the Eligible Employee
would otherwise have received through the Delayed Initial Payment Date if the commencement of the payment of the severance benefits
had not been delayed pursuant to this paragraph and (2) commence paying the balance, if any, of the severance benefits in accordance
with the applicable payment schedule.

 

In no event shall payment
of any severance benefits under the Plan be made prior to an Eligible Employee’s termination date or prior to the effective
date of the Release. If the Company determines that any severance payments or benefits provided under the Plan constitute “deferred
compensation” under Section 409A, and the Eligible Employee’s Separation from Service occurs at a time during the calendar
year when the Release could become effective in the calendar year following the calendar year in which the Eligible Employee’s
Separation from Service occurs, then regardless of when the Release is returned to the Company and becomes effective, the Release
will not be deemed effective, solely for purposes of the timing of payment of severance benefits under this Plan, any earlier than
the latest permitted effective date (the “Release Deadline”). If the Company determines that any severance
payments or benefits provided under the Plan constitute “deferred compensation” under Section 409A, then except to
the extent that severance payments may be delayed until the Delayed Initial Payment Date pursuant to the preceding paragraph, on
the first regular payroll date following the effective date of an Eligible Employee’s Release, the Company shall (1) pay
the Eligible Employee a lump sum amount equal to the sum of the severance benefit payments that the Eligible Employee would otherwise
have received through such payroll date but for the delay in payment related to the effectiveness of the Release and (2) commence
paying the balance, if any, of the severance benefits in accordance with the applicable payment schedule.

 

    	 	7.	 

     

    

 

Section
6.             Transfer
and Assignment. 

 

The rights and obligations
of an Eligible Employee under this Plan may not be transferred or assigned without the prior written consent of the Company. This
Plan shall be binding upon any entity or person who is a successor by merger, acquisition, consolidation or otherwise to the business
formerly carried on by the Company without regard to whether or not such entity or person actively assumes the obligations hereunder
and without regard to whether or not a Change in Control occurs.

 

Section
7.             Right to Interpret and Administer Plan; Amendment and Termination.

 

(a)          Interpretation
and Administration. Prior to the Closing, the Committee shall be the Plan Administrator and shall have the exclusive discretion
and authority to establish rules, forms, and procedures for the administration of the Plan and to construe and interpret the Plan
and to decide any and all questions of fact, interpretation, definition, computation or administration arising in connection with
the operation of the Plan, including, but not limited to, the eligibility to participate in the Plan and amount of benefits paid
under the Plan. The rules, interpretations, computations and other actions of the Committee shall be binding and conclusive on
all persons. Upon and after the Closing, the Plan will be interpreted and administered in good faith by the Representative who
shall be the Plan Administrator during such period. All actions taken by the Representative in interpreting the terms of the Plan
and administering the Plan upon and after the Closing will be final and binding on all Eligible Employees. Any references in this
Plan to the “Committee” or “Plan Administrator” with respect to periods following the Closing shall mean
the Representative.

 

(b)          Amendment.
The Plan Administrator reserves the right to amend this Plan at any time; provided, however, that any amendment of
the Plan will not be effective as to a particular employee who is or may be adversely impacted by such amendment and has an effective
Participation Agreement without the written consent of such employee.

 

(c)          Termination.  Unless otherwise extended by the Committee, the Plan will automatically terminate following
the earlier of (i) satisfaction of all the Company’s obligations under the Plan and (ii) the three year anniversary of the
Effective Date. The Committee may terminate the Plan at any time earlier than the time described in the preceding sentence, however,
any earlier termination of the Plan will not be effective as to a particular employee who is or may be adversely impacted by such
termination and has an effective Participation Agreement without the written consent of such employee.

 

Section
8.             Clawback;
Recovery.

 

All payments and severance
benefits provided under the Plan will be subject to recoupment in accordance with any clawback policy that the Company is required
to adopt pursuant to the listing standards of any national securities exchange or association on which the Company’s securities
are listed or as is otherwise required by the Dodd-Frank Wall Street Reform and Consumer Protection Act or other applicable law.
In addition, the Plan Administrator may impose such other clawback, recovery or recoupment provisions as the Plan Administrator
determines necessary or appropriate, including but not limited to a reacquisition right in respect of previously acquired shares
of common stock of the Company or other cash or property upon the occurrence of a termination of employment for Cause. No recovery
of compensation under such a clawback policy will be an event giving rise to a right to resign for Good Reason, constructive termination,
or any similar term under any plan of or agreement with the Company.

 

    	 	8.	 

     

    

 

Section
9.             No Implied Employment Contract.

 

The Plan shall not be
deemed (i) to give any employee or other person any right to be retained in the employ of the Company or (ii) to interfere with
the right of the Company to discharge any employee or other person at any time, with or without cause, which right is hereby reserved.
This Plan does not modify the at-will employment status of any Eligible Employee.

 

Section
10.           Legal Construction.

 

This Plan is intended
to be governed by and shall be construed in accordance with the Employee Retirement Income Security Act of 1974 (“ERISA”)
and, to the extent not preempted by ERISA, the laws of the State of New Jersey.

 

Section
11.           Claims, Inquiries and Appeals. 

 

(a)            Applications for Benefits and Inquiries. Any application for benefits, inquiries about the Plan or inquiries
about present or future rights under the Plan must be submitted to the Plan Administrator in writing by an applicant (or his or
her authorized representative). The Plan Administrator is:

 

Eagle Pharmaceuticals, Inc.

Human Resources Department

50 Tice Boulevard, Suite 315

Woodcliff Lake, NJ 07677

 

(b)            Denial of Claims. In the event that any application for benefits is denied in whole or in part, the Plan
Administrator must provide the applicant with written or electronic notice of the denial of the application, and of the applicant’s
right to review the denial. Any electronic notice will comply with the regulations of the U.S. Department of Labor. The notice
of denial will be set forth in a manner designed to be understood by the applicant and will include the following:

 

(1)            the specific reason or reasons for the denial;

 

(2)            references to the specific Plan provisions upon which the denial is based;

 

(3)            a description of any additional information or material that the Plan Administrator needs to complete the review
and an explanation of why such information or material is necessary; and

 

    	 	9.	 

     

    

 

(4)            an explanation of the Plan’s review procedures and the time limits applicable to such procedures, including
a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA following a denial on review of
the claim, as described in Section 10(d) below.

 

This notice of denial
will be given to the applicant within 90 days after the Plan Administrator receives the application, unless special circumstances
require an extension of time, in which case, the Plan Administrator has up to an additional 90 days for processing the application.
If an extension of time for processing is required, written notice of the extension will be furnished to the applicant before the
end of the initial 90 day period.

 

This notice of extension
will describe the special circumstances necessitating the additional time and the date by which the Plan Administrator is to render
its decision on the application.

 

(c)           Request
for a Review. Any person (or that person’s authorized representative) for whom an application for benefits is denied,
in whole or in part, may appeal the denial by submitting a request for a review to the Plan Administrator within 60 days after
the application is denied. A request for a review shall be in writing and shall be addressed to:

 

Eagle Pharmaceuticals, Inc.

50 Tice Boulevard, Suite 315

Woodcliff Lake, NJ 07677

 

A request for review must set forth all
of the grounds on which it is based, all facts in support of the request and any other matters that the applicant feels are pertinent.
The applicant (or his or her representative) shall have the opportunity to submit (or the Plan Administrator may require the applicant
to submit) written comments, documents, records, and other information relating to his or her claim. The applicant (or his or her
representative) shall be provided, upon request and free of charge, reasonable access to, and copies of, all documents, records
and other information relevant to his or her claim. The review shall take into account all comments, documents, records and other
information submitted by the applicant (or his or her representative) relating to the claim, without regard to whether such information
was submitted or considered in the initial benefit determination.

 

(d)            Decision
on Review. The Plan Administrator will act on each request for review within 60 days after receipt of the request, unless
special circumstances require an extension of time (not to exceed an additional 60 days), for processing the request for a review.
If an extension for review is required, written notice of the extension will be furnished to the applicant within the initial
60 day period. This notice of extension will describe the special circumstances necessitating the additional time and the date
by which the Plan Administrator is to render its decision on the review. The Plan Administrator will give prompt, written or electronic
notice of its decision to the applicant. Any electronic notice will comply with the regulations of the U.S. Department of Labor.
In the event that the Plan Administrator confirms the denial of the application for benefits in whole or in part, the notice will
set forth, in a manner calculated to be understood by the applicant, the following:

 

    	 	10.	 

     

    

 

(1)            the specific reason or reasons for the denial;

 

(2)            references
to the specific Plan provisions upon which the denial is based;

 

(3)            a statement that the applicant is entitled to receive, upon request and free of charge, reasonable access to,
and copies of, all documents, records and other information relevant to his or her claim; and

 

(4)            a statement of the applicant’s right to bring a civil action under Section 502(a) of ERISA.

 

(e)            Rules
and Procedures. The Plan Administrator will establish rules and procedures, consistent with the Plan and with ERISA, as necessary
and appropriate in carrying out its responsibilities in reviewing benefit claims. The Plan Administrator may require an applicant
who wishes to submit additional information in connection with an appeal from the denial of benefits to do so at the applicant’s
own expense.

 

(f)             Exhaustion of Remedies. No legal action for benefits under the Plan may be brought until the applicant
(i) has submitted a written application for benefits in accordance with the procedures described by Section 10(a) above, (ii) has
been notified by the Plan Administrator that the application is denied, (iii) has filed a written request for a review of
the application in accordance with the appeal procedure described in Section 10(c) above, and (iv) has been notified that
the Plan Administrator has denied the appeal. Notwithstanding the foregoing, if the Plan Administrator does not respond to an Eligible
Employee’s claim or appeal within the relevant time limits specified in this Section 10, the Eligible Employee may bring
legal action for benefits under the Plan pursuant to Section 502(a) of ERISA.

 

Section
12.           Basis
of Payments to and from Plan.

 

The Plan shall be unfunded,
and all cash payments under the Plan shall be paid only from the general assets of the Company.

 

Section
13.           Other Plan Information.

 

(a)            Employer
and Plan Identification Numbers. The Employer Identification Number assigned to the Company (which is the “Plan Sponsor”
as that term is used in ERISA) by the Internal Revenue Service is 20-8179278. The Plan Number assigned to the Plan by the Plan
Sponsor pursuant to the instructions of the Internal Revenue Service is 104.

 

(b)            Ending
Date for Plan’s Fiscal Year. The date of the end of the fiscal year for the purpose of maintaining the Plan’s
records is December 31.

 

    	 	11.	 

     

    

 

(c)            Agent for the Service of Legal Process. The agent for the service of legal process with respect to the
Plan is:

 

Eagle Pharmaceuticals, Inc.

Attention to: Chief Executive Officer

50 Tice Boulevard, Suite 315

Woodcliff Lake, NJ 07677

 

In addition, service
of legal process may be made upon the Plan Administrator.

 

(d)            Plan
Sponsor. The “Plan Sponsor” is:

 

Eagle Pharmaceuticals, Inc.

50 Tice Boulevard, Suite 315

Woodcliff Lake, NJ 07677

(201)326-5300

 

(e)            Plan Administrator. The Plan Administrator is the Committee prior to the Closing and the Representative
upon and following the Closing. The Plan Administrator’s contact information is:

 

Eagle Pharmaceuticals, Inc.

50 Tice Boulevard, Suite 315

Woodcliff Lake, NJ 07677

 

The Plan Administrator
is the named fiduciary charged with the responsibility for administering the Plan.

 

Section
14.           Statement of ERISA Rights.

 

Participants in this
Plan (which is a welfare benefit plan sponsored by Eagle Pharmaceuticals, Inc.) are entitled to certain rights and protections
under ERISA. If you are an Eligible Employee, you are considered a participant in the Plan and, under ERISA, you are entitled to:

 

(a)            Receive Information About Your Plan and Benefits

 

(1)            Examine, without charge, at the Plan Administrator’s office and at other specified locations, such as worksites,
all documents governing the Plan and a copy of the latest annual report (Form 5500 Series), if applicable, filed by the Plan with
the U.S. Department of Labor and available at the Public Disclosure Room of the Employee Benefits Security Administration;

 

(2)            Obtain,
upon written request to the Plan Administrator, copies of documents governing the operation of the Plan and copies of the latest
annual report (Form 5500 Series), if applicable, and an updated (as necessary) Summary Plan Description. The Administrator may
make a reasonable charge for the copies; and

 

(3)            Receive
a summary of the Plan’s annual financial report, if applicable. The Plan Administrator is required by law to furnish each
Eligible Employee with a copy of this summary annual report.

 

    	 	12.	 

     

    

 

(b)           Prudent Actions by Plan Fiduciaries. In addition to creating rights for Plan Eligible Employees, ERISA
imposes duties upon the people who are responsible for the operation of the employee benefit plan. The people who operate the Plan,
called “fiduciaries” of the Plan, have a duty to do so prudently and in the interest of you and other Eligible Employees
and beneficiaries. No one, including your employer, your union or any other person, may fire you or otherwise discriminate against
you in any way to prevent you from obtaining a Plan benefit or exercising your rights under ERISA.

 

(c)            Enforce
Your Rights. If your claim for a Plan benefit is denied or ignored, in whole or in part, you have a right to know why this
was done, to obtain copies of documents relating to the decision without charge, and to appeal any denial, all within certain
time schedules.

 

Under ERISA, there
are steps you can take to enforce the above rights. For instance, if you request a copy of Plan documents or the latest annual
report from the Plan, if applicable, and do not receive them within 30 days, you may file suit in a Federal court. In such a case,
the court may require the Plan Administrator to provide the materials and pay you up to $110 a day until you receive the materials,
unless the materials were not sent because of reasons beyond the control of the Plan Administrator.

 

If you have a claim
for benefits which is denied or ignored, in whole or in part, you may file suit in a state or Federal court.

 

If you are discriminated
against for asserting your rights, you may seek assistance from the U.S. Department of Labor, or you may file suit in a Federal
court. The court will decide who should pay court costs and legal fees. If you are successful, the court may order the person you
have sued to pay these costs and fees. If you lose, the court may order you to pay these costs and fees, for example, if it finds
your claim is frivolous.

 

(d)            Assistance
with Your Questions. If you have any questions about the Plan, you should contact the Plan Administrator. If you have any
questions about this statement or about your rights under ERISA, or if you need assistance in obtaining documents from the Plan
Administrator, you should contact the nearest office of the Employee Benefits Security Administration, U.S. Department of Labor,
listed in your telephone directory or the Division of Technical Assistance and Inquiries, Employee Benefits Security Administration,
U.S. Department of Labor, 200 Constitution Avenue N.W., Washington, D.C. 20210. You may also obtain certain publications about
your rights and responsibilities under ERISA by calling the publications hotline of the Employee Benefits Security Administration.

 

    	 	13.	 

     

    

 

Appendix
A

 

Eagle
Pharmaceuticals, Inc. 

 

Severance
Benefit Plan 

 

Participation
Agreement 

 

Name:                  ___________________

 

Section
1.             Eligibility.

 

You have been designated
as eligible to participate in the Eagle Pharmaceuticals, Inc. Severance Benefit Plan (the “Plan”), a
copy of which is attached to this Participation Agreement (the “Agreement”). Capitalized terms not explicitly
defined in this Agreement but defined in the Plan shall have the same definitions as in the Plan. Except as otherwise provided
below, you will receive the benefits set forth below if you meet all the eligibility requirements set forth in the Plan, including,
without limitation, executing the required Release within the applicable time period set forth therein and provided that such Release
becomes effective in accordance with its terms. Notwithstanding the schedule for provision of benefits as set forth below, the
schedule and timing of payment of any benefits under this Agreement is subject to any delay in payment that may be required under
Section 5 of the Plan.

 

Section
2.             Change
in Control Severance Benefits.

 

If you are terminated
in a Covered Termination that occurs during the Change in Control Period, you will receive the severance benefits set forth in
this Section 2. All severance benefits described herein are subject to standard deductions and withholdings.

 

(a)            Base
Salary Payment. You shall receive a cash payment in an amount equal to [______] months1
(the “CIC Severance Period”) of payment of your Base Salary. The Base Salary payment will
be paid to you in a lump sum cash payment no later than the second regular payroll date following the later of (i) the effective
date of the Release or (ii) the Closing, but in any event not later than March 15 of the year following the year in which
your Separation from Service occurs.

 

(b)             Bonus
Payment. You will be entitled to a cash payment in an amount equal to [__]2
times the greater of (i) the annual target cash bonus established for you pursuant to the annual performance bonus
or annual variable compensation plan established by the Committee (or any authorized committee or designee thereof) for the year
in which your Covered Termination occurs and (ii) the actual annual cash bonus earned by you from the Company for the year prior
to the year in which your Covered Termination occurs. For the avoidance of doubt, the annual bonus for purposes of calculating
the foregoing benefit will be calculated as if you had provided services to the Company for the entire applicable year and ignoring
any reduction in your Base Salary that would give rise to your right to resignation for Good Reason. Such payment shall be paid
in a lump sum cash payment no later than the second regular payroll date following the later of (i) the effective date of
the Release or (ii) the Closing, but in any event not later than March 15 of the year following the year in which your Separation
from Service occurs.

 

 

1
24 months for CEO; 18 months for other NEO participants.

2
2 for CEO; 1.5 for other NEO participants.

 

     

     

    

 

(c)             Payment of Continued Group Health Plan Benefits. If you timely elect continued group health plan continuation
coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) following your Covered
Termination date, the Company shall pay directly to the carrier the full amount of your COBRA premiums on behalf of you for your
continued coverage under the Company’s group health plans, including coverage for your eligible dependents, until the earliest
of (i) the end of the CIC Severance Period following the date of your Covered Termination, (ii) the expiration of your eligibility
for the continuation coverage under COBRA, or (iii) the date when you become eligible for substantially equivalent health insurance
coverage in connection with new employment (such period from your termination date through the earliest of (i) through (iii), the
“COBRA Payment Period”). Upon the conclusion of such period of insurance premium payments made by the
Company, you will be responsible for the entire payment of premiums (or payment for the cost of coverage) required under COBRA
for the duration of your eligible COBRA coverage period, if any. For purposes of this Section, (1) references to COBRA shall be
deemed to refer also to analogous provisions of state law and (2) any applicable insurance premiums that are paid by the Company
shall not include any amounts payable by you under an Internal Revenue Code Section 125 health care reimbursement plan, which amounts,
if any, are your sole responsibility. You agree to promptly notify the Company as soon as you become eligible for health insurance
coverage in connection with new employment or self-employment.

 

Notwithstanding the
foregoing, if at any time the Company determines, in its sole discretion, that it cannot provide the COBRA premium benefits without
potentially incurring financial costs or penalties under applicable law (including, without limitation, Section 2716 of the Public
Health Service Act), then in lieu of paying COBRA premiums directly to the carrier on your behalf, the Company will instead pay
you on the last day of each remaining month of the COBRA Payment Period a fully taxable cash payment equal to the value of your
monthly COBRA premium for the first month of COBRA coverage, subject to applicable tax withholding (such amount, the “Special
Severance Payment”), such Special Severance Payment to be made without regard to your election of COBRA coverage
or payment of COBRA premiums and without regard to your continued eligibility for COBRA coverage during the COBRA Payment Period.
Such Special Severance Payment shall end upon expiration of the COBRA Payment Period.

 

(d)             Equity
Acceleration. The vesting and exercisability of each outstanding unvested stock option, unit or other stock award, as applicable,
that you hold covering Company common stock that vests solely subject to your continued service with the Company over time (each,
an “Time-Vesting Equity Award”) shall be accelerated in full and any reacquisition or repurchase rights
held by the Company in respect of common stock issued pursuant to any Equity Award granted to you shall lapse in full. If you
hold outstanding unvested equity awards covering Company common stock that vest based on performance goals over a performance
period that has not ended as of the Covered Termination (each, a “Performance Equity Award”), such award
shall be governed by the terms of the individual grant notice and award agreements evidencing such awards or instead shall accelerate
vesting with respect to the target number of shares subject to such award, whichever treatment results in the greater benefit
to you. Notwithstanding anything to the contrary set forth herein, all of your Time-Vesting Equity Awards and Performance Equity
Awards (together, the “Equity Awards”) shall remain subject to the terms of the Equity Plan (or other
applicable Company plan).

 

    	 	2.	 

     

    

 

(e)             Extension
of Post-Termination Exercise Period. All outstanding Equity Awards which carry a right to exercise that you hold as of the
date of your [Covered Termination]3
[cessation of Continuous Service (as defined in the Equity Plan which may, for the avoidance of doubt, occur after your Covered
Termination if, for example, you continue to provide services as a member of the board of directors of the Company (or its successor,
if applicable)]4, to the extent
vested as of such date (including any vesting acceleration as a result of such Covered Termination or Change in Control) will
expire on the earlier of (A) the original term of such outstanding Equity Awards as set forth in the applicable award agreement
or the equity incentive plan, subject to earlier termination in the event of a Change in Control as set forth in the terms of
the applicable equity incentive plan and definitive agreement for such Change in Control transaction, and (B) [twelve (12)
months following your Covered Termination]5
[twenty-four (24) months following your cessation of Continuous Service (as defined in the Equity Plan)]6.

 

Section
3.             Non-Change
in Control Severance Benefits.

 

If you are terminated
in a Covered Termination that occurs at a time that is not during the Change in Control Period, you will receive the severance
benefits set forth in this Section 3. All severance benefits described herein are subject to standard deductions and withholdings.

 

(a)             Base
Salary Payment. You shall receive a cash payment in an amount equal to [______] months7
(the “Severance Period”) of payment of your Base Salary. The Base Salary payment will be
paid to you in a lump sum cash payment no later than the second regular payroll date following the effective date of the Release,
but in any event not later than March 15 of the year following the year in which your Separation from Service occurs.

 

(b)             Bonus
Payment. You will be entitled to a cash payment in an amount equal to the annual target cash bonus established for you pursuant
to the annual performance bonus or annual variable compensation plan established by the Committee (or any authorized committee
or designee thereof) for the year in which your Covered Termination occurs, calculated as if you had provided services to the
Company for the entire applicable year and ignoring any reduction in your Base Salary that would give rise to your right to resignation
for Good Reason. Such bonus payment shall be paid in a lump sum cash payment no later than the second regular payroll date following
the effective date of the Release, but in any event not later than March 15 of the year following the year in which your Separation
from Service occurs.

 

 

3
Insert for all NEO participants other than CEO.

4
Insert for CEO.

5
Insert for all NEO participants other than CEO.

6
Insert for CEO.

7
18 months for CEO; 12 months for other NEO participants.

 

    	 	3.	 

     

    

 

(c)             Payment
of Continued Group Health Plan Benefits. You will receive the COBRA benefits on the conditions and at the times described
in Section 2(c) above, but the time period used for purposes of calculating such benefits shall be the Severance Period (rather
than the CIC Severance Period).

 

(d)             Extension of Post-Termination Exercise Period. All outstanding Equity Awards which carry a right to exercise
that you hold as of the date of your [Covered Termination]8
[cessation of Continuous Service (as defined in the Equity Plan which may, for the avoidance of doubt, occur after your Covered
Termination if, for example, you continue to provide services as a member of the board of directors of the Company (or its successor,
if applicable)]9, to the extent vested
as of such date (including any vesting acceleration as a result of such Covered Termination) will expire on the earlier of (A) the
original term of such outstanding Equity Awards as set forth in the applicable award agreement or the equity incentive plan, subject
to earlier termination in the event of a Change in Control as set forth in the terms of the applicable equity incentive plan and
definitive agreement for such Change in Control transaction, and (B)  [twelve (12) months following your Covered Termination]10
[twenty-four (24) months following your cessation of Continuous Service (as defined in the Equity Plan)]11.

 

(e)             Equity Acceleration. The vesting and exercisability of each Time-Vesting Equity Award shall be accelerated
[in full and any reacquisition or repurchase rights held by the Company in respect of common stock issued pursuant to any Time-Vesting
Equity Award granted to you shall lapse in full]12[and
any reacquisition or repurchase rights held by the Company in respect of common stock issued pursuant to any Time-Vesting Equity
Award granted to you shall lapse with respect to the number of shares of common stock that were scheduled to vest pursuant to the
vesting schedule of such Time-Vesting Equity Award over the twelve (12)-month period immediately following your Separation from
Service, notwithstanding your Separation from Service]13.
If you hold any outstanding unvested Performance Equity Award, the treatment of such awards shall be governed by the terms of the
individual grant notice and award agreements evidencing such awards. Notwithstanding anything to the contrary set forth herein,
all of your Equity Awards shall remain subject to the terms of the Equity Plan (or other applicable Company plan) under which such
Equity Award was granted.

 

For the avoidance of
doubt, in no event shall you be entitled to benefits under both Section 2 and this Section 3. If you are eligible for severance
benefits under both Section 2 and this Section 3, you shall receive the benefits set forth in Section 2 and such benefits shall
be reduced by any benefits previously provided to you under Section 3.

 

 

8
Insert for all NEO participants other than CEO.

9
Insert for CEO.

10
Insert for all NEO participants other than CEO.

11
Insert for CEO.

12
Insert for CEO.

13
Insert for all NEO participants other than CEO.

    	 	4.	 

     

    

 

Section
4.             Death
or Disability Termination Severance Benefits.

 

If you experience a Death
or Disability Termination, you will receive the severance benefits set forth in this Section 4. All severance benefits described
herein are subject to standard deductions and withholdings.

 

(a)             Equity
Acceleration. The vesting and exercisability of each Time-Vesting Equity Award shall be accelerated in full and any reacquisition
or repurchase rights held by the Company in respect of common stock issued pursuant to any Time-Vesting Equity Award granted to
you shall lapse in full. Notwithstanding anything to the contrary set forth herein, all of your Time-Vesting Equity Awards shall
remain subject to the terms of the Equity Plan (or other applicable Company plan).

 

(b)             Extension of Post-Termination Exercise Period. All outstanding Equity Awards which carry a right to exercise
that you hold as of the date of your Death or Disability Termination, to the extent vested as of your Death or Disability Termination
(including any vesting acceleration as a result of such Death or Disability Termination) will expire on the earlier of (A) the
original term of such outstanding Equity Awards as set forth in the applicable award agreement or the equity incentive plan, subject
to earlier termination in the event of a Change in Control as set forth in the terms of the applicable equity incentive plan and
definitive agreement for such Change in Control transaction, and (B) twenty-four (24) months following your Death or Disability
Termination.

 

For the avoidance of
doubt, if you are entitled to benefits under this Section 4 you will not be eligible for benefits under Section 2 or Section 3.

 

Section
5.              Change
in Control Acceleration Upon Acquiror’s Failure to Assume, Continue or Substitute. If, in connection with a Change
in Control, any outstanding unvested Equity Award that you hold shall terminate and will not be assumed or continued by the successor
or acquiror entity in such Change in Control or substituted for a similar award of the successor or acquiror entity (a “Terminating
Award”), then, you will become vested, with respect to any then unvested portion of such Terminating Award, effective
immediately prior to, but subject to the consummation of such Change in Control. With respect to any such outstanding Terminating
Award that vests based on performance goals over a performance period that has not ended as of the Change in Control, such award
shall be governed by the terms of the individual grant notice and award agreements evidencing such awards or instead shall accelerate
vesting with respect to the target number of shares subject to such award under this Section 5, whichever treatment results in
the greater benefit to you. For the avoidance of doubt, the benefits under this Section 5 are contingent on a Change in Control
and do not require your Covered Termination or other termination of service. In addition, you may be eligible for benefits under
this Section 5 in addition to benefits under Section 2 or Section 4 and in such case, you shall receive benefits under both sections,
without duplication.

 

    	 	5.	 

     

    

 

Section
6.             Acknowledgements.

 

As a condition to participation
in the Plan, you hereby acknowledge each of the following:

 

(a)            The benefits that may be provided to you under this Agreement are subject to all of the terms of the Plan, which
is incorporated into and becomes part of this Agreement, including but not limited to certain reductions and termination under
Section 2 and Section 3 of the Plan.

 

(b)           Your
eligibility for and receipt of any severance benefits to which you may become entitled as described in Section 2, Section 3 or
Section 4 above is expressly contingent upon your compliance with the terms and conditions of the Release and the terms and conditions
of any proprietary information, inventions assignment, non-competition and non-solicitation agreement and/or other similar agreement
with the Company, as may be amended from time to time (the “Proprietary Agreement”). Severance benefits
under this Agreement shall immediately cease in the event of your violation of the provisions of the Release or the Proprietary
Agreement.

 

(c)            This
Agreement and the Plan supersede and replace the Company’s Officer Severance Benefit Plan effective August 4, 2015 and any
other change in control or severance benefits on the terms described in Section 2 of the Plan.

 

To accept the terms
of this Agreement and participate in the Plan, please sign and date this Agreement in the space provided below and return it to
_____________________ no later than _________, ____.

 

	Eagle Pharmaceuticals,
    Inc.	 

 

	By:	 	 

 

	Michael Graves	 
	Chairman of the Board of Directors	 

 

	Eligible Employee	 

	 	 
	[Insert Name]	 
	 	 
	Date:	 	 

 

    	 	6.Blueprint

 

SECOND AMENDMENT TO FORBEARANCE AGREEMENT

 

AND
FOURTH AMENDMENT TO CREDIT AGREEMENT

 

THIS
SECOND AMENDMENT TO FORBEARANCE AGREEMENT AND FOURTH AMENDMENT TO
CREDIT AGREEMENT (this “Amendment”) dated as of
December 12,
2019, is entered into by and among AEROCENTURY CORP., a Delaware
corporation (“Borrower”), the
Guarantors (defined below), the Lenders (defined below) and
MUFG UNION BANK, N.A., a
national banking association, as administrative agent for the
Lenders (in such capacity, “Agent”), with reference
to the following facts:

 

RECITALS

 

A.           Borrower,
JetFleet Holding Corp., a California corporation
(“Holding
Guarantor”), and JetFleet Management Corp., a
California corporation (“Management Guarantor” and
together with Holding Guarantor, collectively the
“Guarantors”), on the one
hand, and Agent and the lenders (collectively, the
“Lenders”) under that
certain Third Amended and Restated Credit Agreement dated as of
February 19, 2019 (as amended by that First Amendment of
Forbearance Agreement and First Amendment to Credit Agreement dated
as of November 13, 2019 (the “First Amendment”) and
that Second Amendment to Credit Agreement and Consent for Sale of
Collateral dated as of November 26, 2019 (the
“Second
Amendment”), and as may be further amended, extended,
renewed, supplemented or otherwise modified from time to time, the
“Credit
Agreement”), on the other hand, are parties to that
certain Forbearance Agreement dated as of October 28, 2019, as
amended pursuant to the First Amendment (as may be further amended,
extended, renewed, supplemented or otherwise modified from time to
time, the “Forbearance
Agreement”).

 

B.           Pursuant
to the Forbearance Agreement, (i) Agent and the Lenders agreed
to temporarily forbear solely during the Forbearance Period from
exercising the Enforcement Actions as a result of the occurrence
and continuance of the Specified Defaults described on Exhibit A to
the Forbearance Agreement and (ii) MUFG Bank, Ltd.
(“MUFG
LTD”) agreed to temporarily forbear from exercising
Termination Rights as a result of such Specified
Defaults.

 

C.           On
November 27, 2019, Borrower delivered to Agent that certain
Compliance Certificate covering the Fiscal Quarter ending
September 30, 2019 (“Q3 Compliance
Certificate”), which disclosed violation of several
financial covenants (“Q3 Events of Default”).
The Q3 Events of Default include the following Events of Default
that are Specified Defaults: Borrower’s failure to maintain
for the third Fiscal Quarter of 2019 (i) Minimum Recourse Debt
Interest Coverage Ratio of at least 2.25x as required by
Section 6.15.4
of the Credit Agreement, (ii) Minimum Recourse Debt Service
Coverage Ratio of at least1.05x as required by Section 6.15.5 of the
Credit Agreement, and (iii) no net loss as required by
Section 6.15.7
of the Credit Agreement. In addition to the foregoing, the Q3
Events of Default include the following additional Events of
Default (collectively, the “New Events of Default”):
Borrower’s failure to maintain for the third Fiscal Quarter
of 2019: (a) Interest Coverage Ratio of at least 2.25x as
required by Section 6.15.2 of the
Credit Agreement, (b) Debt Service Coverage Ratio of at least
1.05x as required by Section 6.15.3 of the
Credit Agreement, and (c) Minimum Tangible Net Worth as
required by Section
6.15.6 of the Credit Agreement.

 

D.           Each
New Event of Default constitutes a Forbearance Termination Event,
thereby causing the occurrence of a Forbearance Termination Date on
November 27, 2019. On December 3, 2019, Agent delivered to
Borrower and Guarantors a notice of default and reservation of
rights letter providing notice of the occurrence of the Forbearance
Termination Date and reservation of the respective rights and
remedies of Agent, the Lenders and MUFG LTD, which notice is
acknowledged by Borrower and Guarantors as proper and
valid.

 

E.           Pursuant
to that certain Temporary Waiver and Consent dated as of December
4, 2019 (the “Temporary Waiver”), the
Lenders agreed to temporarily waive the Specified Defaults and New
Events of Default and MUFG LTD temporarily waive any event of
default that may arise under the Swap Contracts (defined in the
Forbearance Agreement) as a result of the Specified Defaults and
New Events of Default (the “Swap Default”), solely in
order for the Lenders to consider Borrower’s request for
approval of the November 27 Budget for the purposes of making
disbursements from the Restricted Account for the week ending
December 6th, all as set forth
and subject to the terms of the Temporary Waiver.

 

F.           Borrower
and Guarantors have requested that (i) Agent and the Lenders
(a) waive the Forbearance Termination Events occurring as a
result of the New Events of Default, agree to continue forbear from
exercising Enforcement Actions with respect to the Specified
Defaults, New Events of Defaults and any Event of Default under
Section 9.1.18
of the Credit Agreement that may arise from the Swap Default and,
in conjunction therewith, temporarily waive compliance with certain
requirements in the Credit Agreement to permit the reborrowing of
LIBOR Loans during the Forbearance Period, (b) consent to the
sale of the Collateral consisting of one SAAB-SCANIA model SAAB
340B aircraft bearing manufacturer’s serial number 340B-454
(“454
Aircraft”) and two General Electric model CT7-9B
aircraft engines bearing manufacturer’s serial numbers 785715
and 785784 (together, the “454 Engines” and,
collectively with the 454 Aircraft, the “454 Collateral”),
(c) permit the disbursement from the Restricted Account to
cover Borrower’s Liquidity Needs for the week ending December
13th as
identified on Borrower’s Cash Flow Budget delivered to
Lenders on November 27, 2019 (the “November 27 Budget”), and
(d) amend the Credit Agreement in certain respects, and
(ii) MUFG LTD continue to temporarily forbear from exercising
Termination Rights with respect to the Swap Default.

 

G.           Agent,
the Lenders and MUFG LTD are willing to do so on the terms and
conditions set forth in this Amendment. MUFG LTD is entering into
this Amendment with respect to Sections 4(a) through
(d)
below.

 

NOW,
THEREFORE, for good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the parties hereby agree
as follows:

 

AGREEMENT

 

1. Incorporation of Recitals. Each
of the above Recitals is incorporated herein as true and correct in
all material respects and is relied upon by Agent and the Lenders
in agreeing to the terms of this Amendment.

 

2. Defined Terms. Any and all
initially-capitalized terms used in this Amendment (including,
without limitation, in the Recitals to this Amendment), without
definition shall have the respective meanings specified in the
Forbearance Agreement and/or Credit Agreement, as
applicable.

 

3. Acknowledgments. Borrower and
Guarantors each restates and reaffirms the acknowledgments each
made in Section 3 of the
Forbearance Agreement as of the Amendment Effective Date as such
term is defined in Section 10 hereof. Except
as expressly set forth herein, all terms, conditions, covenants,
representations and warranties contained in the Credit Agreement,
the other Loan Documents and all rights of Agent and the Lenders
and all obligations of Borrower and the Guarantors thereunder,
remain in full force and effect.

 

4. Forbearance; Temporary
Waiver.

 

(a) Waiver of Forbearance Termination
Events. The Lenders and MUFG LTD hereby waive the
Forbearance Termination Events occurring under the Forbearance
Agreement as a result of the New Events of Defaults and any Event
of Default under Section 9.1.18 of the
Credit Agreement that may arise from the Swap Default.

 

(b) Specified Defaults. The
Specified Defaults under the Forbearance Agreement shall hereby
include the New Events of Default and any Event of Default under
Section 9.1.18
of the Credit Agreement that may arise from the Swap Default and
the term “Specified Defaults” in the Forbearance
Agreement and Exhibit
A thereto are hereby each modified to include the New Events
of Default and the Event of Default under Section 9.1.18 of the Credit
Agreement with respect to the Swap Default.

 

(c) Forbearance Period.
Section 4(a)(i)
of the Forbearance Agreement is hereby amended to read as
follows:

 

“(i)            

11:59 p.m. (New
York City time) on January 14, 2020;”

 

(d) Temporary Waiver. The
provisions of the Credit Agreement and the other Loan Documents to
the contrary notwithstanding, subject to the terms and conditions
of the Forbearance Agreement (as amended hereby) and as long as a
Forbearance Termination Event has not then occurred, Agent and the
Lenders hereby agree to temporarily waive compliance with the
following requirements of the Credit Agreement for the reborrowing
of LIBOR Loans: (i) the requirement of Section 2.1.1 of the Credit
Agreement that Loans shall be made as Base Rate Loans if a Default
or Event of Default has occurred and is continuing, and (ii) the
requirements of Section
2.1.4(b) of the Credit Agreement that (1) no Default or
Event of Default shall then exist and be continuing on the date of
such reborrowing and (2) that Borrower provide two
(2) Business Days’ notice prior to the date of such
reborrowing (such requirements in the forgoing clauses (i) and (ii)
are referred to collectively herein as the “Reborrowing
Requirements”). For clarity, the purpose of this
temporary waiver of the Reborrowing Requirements is solely to
permit the reborrowing (i.e., rollover) of outstanding LIBOR
Loans and not for the extension for any new Loans (and Borrower
acknowledges its covenant under the Forbearance Agreement to not
request borrowing of new Loans). Each Obligor hereby acknowledges
and agrees each of the Specified Default (as such term is amended
hereby) exists as of the date hereof and will continue to exist
after the Amendment Effective Date.

 

(e) Limited Effect of Waiver. The
waiver set forth in Section 4(d) above shall
be limited precisely as written and shall not be deemed (a) to be a
waiver of any other term or condition of the Credit Agreement or
the other Loan Documents, (b) to be a waiver of any Default or
Event of Default (including, without limitation, the Specified
Defaults, as such term is amended hereby), (c) to prejudice
any right or remedy which Agent or the Lenders may now have or may
have in the future under or in connection with the Credit Agreement
or the other Loan Documents, nor shall the entering into this
Amendment or the Forbearance Agreement (as amended hereby) preclude
agent or the Lenders from refusing to enter into any further
waivers or amendments with respect to the Credit Agreement or any
other Loan Document, (d) to be a consent to any future waiver
under the Credit Agreement or the other Loan Documents, or
(e) to constitute a course of dealing or other basis for
altering any Obligations or any other contract or
instrument.

 

(f) Extension of Cure Deadline.
Borrower acknowledges that there exists a Borrowing Base Deficiency
that constitutes a Default (“Borrowing Base Default”)
and will constitute an Event of Default if not cured by January 13,
2020 (the “Deficiency Cure
Deadline”). It is hereby confirmed that the Borrowing
Base Default is a Specified Default under the Forbearance Agreement
as amended hereby. Notwithstanding the provisions of the Credit
Agreement or any other Loan Documents, the Deficiency Cure Deadline
is hereby extended to February 12, 2020. For the avoidance of
doubt, the failure to cure the Borrowing Deficiency Default by the
Deficiency Deadline as extended hereby shall constitute an
immediate Event of Default under the Credit Agreement.

 

(g) Interest Rate Increase. From
and after the Amendment Effective Date, all LIBOR Loans under the
Credit Agreement shall bear interest at the Applicable LIBOR Rate
in effect after giving effect to the amendments to the Credit
Agreement described below (which interest rate shall remain in
effect notwithstanding any occurrence of a Forbearance Termination
Date).

 

5. Amendments to Forbearance
Agreement.

 

(a) Section 5 of the
Forbearance Agreement titled “Covenants” is hereby
amended by adding the following paragraphs immediately below
paragraph (c) thereof:

 

(d)            

Lenders’ Consultant. Each
Obligor acknowledges that Agent and the Lenders are entitled under
the Credit Agreement to retain (or cause Agent’s counsel to
retain) at Borrower’s costs a financial advisor or consultant
(“Lenders’
Consultant”) to review, analyze and make
recommendations with respect to, Obligor’s historical and
projected financial and operating performance, liquidity, financial
statements, any proposed sale, financial restructuring or other
strategic alternatives and any other matter relating to Obligors
and the Collateral. Borrower shall pay or reimburse Agent and the
Lenders upon demand for the fees, costs and expenses of
Lenders’ Consultant. Each Obligor hereby agrees to (i)
provide Lender's Consultant reasonable access during normal
business hours to the offices, properties, officers, employees,
accountants, auditors, counsel and other representatives, books and
records of Obligors, and (ii) furnish to Lenders’ Consultant
such financial, operating and property related data and other
information as Lenders’ Consultant reasonably requests. Each
Obligor hereby (1) agrees and acknowledges that all of
Lenders’ Consultant's analyses, conclusions, reports and
other work product are confidential and covered by the
attorney-work product privilege and the common interest privilege
and, consequently, are exempt from disclosure to any Obligor or any
other Person, (2) acknowledges and agrees that Agent, the Lenders
and Lenders’ Consultant may use and share, without liability,
among themselves and their respective advisors, attorneys,
consultants, accounts, and agents information regarding such
Obligor, the Collateral, the Credit Facility and the Loan
Documents, including, without limitation, personally identifiable
information and data, financial information, projections, lessee
information, and (3) waives any rights or claims with respect
to such use or sharing, including regarding financial privacy and
data protection laws and regulations.

 

(e)            

Lender Update. Borrower agrees
to make available, on as frequently as a bi-weekly basis, senior
management of Borrower and, at Borrower’s option or upon
request of Agent, Borrower’s financial advisor or other
advisors for meetings or conference calls with Agent and the
Lenders (and their representatives and consultants), at such dates
and times to be provided by Agent upon reasonable notice. The
purpose of such meetings will be to discuss the status of the
financial, collateral, and operational condition, businesses,
liabilities, assets, and prospects of Borrower and the Collateral,
any sale, refinance or other strategic transaction efforts.
Borrower and Guarantors shall promptly provide copies of all
non-privileged non-confidential written materials provided to, or
produced by, Borrower or Guarantors in connection with any sale,
refinance, other strategic transaction efforts (including, without
limitation, any letters of intent, confidentiality agreements,
draft purchase documents, commitment letters, and correspondence to
or from any Governmental Authority) and material third party
reports relating to the financial, collateral, or operational
performance of Borrower and the Collateral or any other
non-privileged non-confidential written material as Agent may
reasonably request from time to time. Without limiting the
foregoing, Borrower agrees to notify Agent immediately upon either
Borrower becoming aware of any material change or development
relating to any sale or refinance efforts or to the financial,
collateral, or operational condition, businesses, assets,
liabilities, or prospects of Borrower or the
Collateral.

 

(f)            

Collateral Report. Borrower
shall deliver to the Lenders, on a bi-weekly basis beginning on
December 30, 2019, a detailed report containing the following
information, satisfactory to the Lenders, regarding the aircraft
and engines that are part of the Collateral (the
“Collateral
Report”): (i) the base location of the Collateral
Covered thereby and the country in which each aircraft is
registered and the countries to which it is flown by its Lessee,
(ii) whether such Collateral is on Lease, (iii) if it is on Lease,
whether there is a default under such Lease and, if there is such a
default, a description of the default and Borrower’s intended
action with respect thereto, and (iv)  with respect to
aircraft bearing manufacturer’s serial numbers 15128, 15207,
15215, an accounting of the ongoing expenses for storage, insurance
and similar expenses for such Collateral, the date and time of any
visits by or on behalf of Borrower to monitor such Collateral and
the name of the person(s) undertaking such visits (beginning with
the most recent visit made as of the date hereof and continuing for
any visits made thereafter), and an update with respect to the
marketing process of such aircraft.

 

(g)            

Restricted Account. Each
Obligor hereby acknowledges the establishment of the restricted
account, bearing account number XXXXX00046
(“Restricted Account”),
with MUFG Union Bank, N.A., in its capacity as depository bank as
set forth in the Second Amendment and recognizes Agent’s
control over the disposition of funds in the Restricted Account.
Borrower agrees to comply with Sections 8 (Restricted Account)
and 9 (Cash Flow
Budgets Review; Disbursement) of the Second Amendment.

 

(h)            

Excess Proceeds. Borrower
covenants and agrees that Borrower shall immediately use any Excess
Proceeds Borrower receives from the disposition of the Excluded
Assets to repay the Loans.

 

6. Amendments to Credit Agreement.
The Credit Agreement shall be amended as follows:

 

(a) The following
definition is hereby added to Section 1.1 in
alphabetical order:

 

“Base Rate Cash Margin”
means a per annum rate of interest equal to 2.75%.

 

“LIBOR Cash Margin” means
a per annum rate of interest equal to 6.00%.

 

“PIK Margin” means a per
annum rate of interest equal to 2.50%.

 

(b) The following terms
and their respective definitions set forth in Section 1.1 of the Credit
Agreement shall be deleted and replaced with the
following:

 

“Applicable Base Rate
Margin” means, for any period, the sum of (a) the Base
Rate Cash Margin for such period and (b) the PIK Margin for such
Period.

 

“Applicable LIBOR Margin”
means, for any period, the sum of (a) the LIBOR Cash Margin for
such period and (b) the PIK Margin for such period.

 

(c) The term
“Pricing Leverage” and its definition set forth in
Section 1.1 of the
Credit Agreement shall be deleted and the reference to such term in
second paragraph of the form Compliance Certificate attached as
Exhibit C to the Credit Agreement, along with first numbered
paragraph of the form Compliance Certificate, is hereby
deleted.

 

(d) Sections 2.1.4(a)(i) and
(b) are hereby
amended to delete “and in an integral multiple of
$100,000.00” where they appear in such Sections. The form of
Borrowing Notice attached as Exhibit B to the Credit Agreement
is amended to delete such sentence from its footnote number
1.

 

(e) Section 2.2.1(a) of the Credit
Agreement is amended by adding the following at the end
thereof:

 

Notwithstanding the
foregoing, in lieu of cash payment, interest accruing on such Base
Rate Loan at the PIK Margin shall be due and payable in-kind on the
payment date thereof by being capitalized and added to the
outstanding principal balance of such Base Rate Loan on such date
(after which time such capitalized interest shall no longer be
treated as accrued and unpaid interest but instead shall be treated
as a portion of the outstanding principal balance of the Base Rate
Loans and bear interest in accordance with this Agreement for all
purposes).

 

(f) Section 2.2.1(b) of the Credit
Agreement is amended by adding the following at the end
thereof:

 

Notwithstanding the
foregoing, in lieu of cash payment, interest accruing on such LIBOR
Loan at the PIK Margin shall be due and payable in-kind on each
Payment Date by being capitalized and added to the outstanding
principal balance of such LIBOR Loan on such date (after which time
such capitalized interest shall no longer be treated as accrued and
unpaid interest but instead shall be treated as a portion of the
outstanding principal balance of the LIBOR Loans and bear interest
in accordance with this Agreement for all purposes).

 

(g) Section 2.2.1(c) of the Credit
Agreement shall be deleted and replaced with the
following:

 

(c)            

Reserved.

 

(h) Section 2.6.3 of the Credit
Agreement is amended by deleting and replacing second sentence
thereof with the following:

 

Unless
the Requisite Lenders otherwise agree in writing, upon (i) the sale
of any Collateral for a sale price that exceeds $200,000.00 or (ii)
the receipt of proceeds in excess of $200,000.00 from any recovery
under any applicable insurance policies (or otherwise) in
connection with an Event of Loss, Borrower shall repay immediately
all or such portion of the Loans in an amount equal to the proceeds
from such sale or recovery.

 

(i) Section 3.3.3 of the Credit
Agreement is amended as follows:

 

3.3.3                       

For the purposes of
allowing Agent to conduct a Field Examination, Borrower shall, with
respect to each owned, leased, or controlled property or facility,
during normal business hours: (1) provide access to such facility
or property to Agent and any of its officers, employees and Agent,
as frequently as Agent determines to be appropriate; (2) permit
Agent and any of its officers, employees and Agent to inspect,
audit and make extracts from all of Borrower’s books and
records; and (3) subject to the Lessee’s rights under any
Lease, permit Agent to inspect, review, evaluate and make physical
verifications and appraisals of any Equipment and other Collateral
in any manner and through any medium that Agent considers
advisable, and Borrower shall provide to Agent, at Borrower’s
cost and expense, such clerical and other assistance as may be
requested with regard thereto. Borrower shall make available to
Agent and its counsel, as quickly as practicable under the
circumstances, originals or copies of all of Borrower’s books
and records and any other instruments and documents which Agent may
request. Borrower shall deliver any document or instrument
necessary for Agent, as it may from time to time request, to obtain
records from any service bureau or other Person that maintains
records for Borrower. Agent shall be entitled to cause a Field
Examination to be completed at times and as often as it deems
necessary in its sole discretion. Borrower shall reimburse Agent
upon demand for the expense of such Field Examinations whether the
examination is performed by Agent or a third party approved by
Agent. Borrower’s obligation to reimburse Agent for the costs
of such Field Examinations shall not exceed $20,000 per year. At
all times, it is understood and agreed by Borrower that all
expenses in connection with any such Field Examination which may be
incurred by Borrower, any officers and employees thereof and the
attorneys and independent certified public accountants therefor
shall be expenses payable by Borrower and shall not be expenses of
Agent or the Lenders nor part of the foregoing cap.

 

(j) Section 6.6 of the Credit
Agreement is hereby amended and replaced with the
following:

 

6.6            

Inspection Rights. At any time
during regular business hours and as often as requested, permit
Agent, or any authorized employee or representative thereof, to
examine, audit and make copies and abstracts from the records and
books of account of, and to visit and inspect the Property of,
Borrower and its Subsidiaries and to discuss the affairs, finances
and accounts of Borrower and its Subsidiaries with any of its
officers, key employees or accountants. In addition, Agent shall
have the right to cause a Field Examination to be completed as
described in Section 3.3.3.

 

(k) Section 6.25 of the Credit
Agreement is amended by deleting and replacing subsection (b)
thereof with the following:

 

Except
as provided in subsection (c) below, if the sale or disposition of
an Excluded Asset generates funds in excess of the amount
sufficient to prepay or repay the Permitted Excluded Subsidiary
Financing secured by such Excluded Asset and pay the third-party
costs associated with such prepayment or repayment and sale (the
“Excess
Proceeds”), Borrower shall immediately cause such
Excess Proceeds to be used to repay the Loans.

 

(l) Section 12.8.2 of the Credit
Agreement is amended by deleting the following sentence from clause
(i) thereof:

 

and,
provided no Default or Event of Default then exists,
Borrower

 

7. Consent to Sale.

 

(a) The Lenders consent
to sale of the 454 Collateral and the release of the security
interests and liens granted under the Collateral Documents solely
with respect to 454 Collateral. The Lenders hereby authorize Agent
to enter into and deliver appropriate lien releases, filings and
related instruments necessary to effectuate the terms of this
Agreement and the discharge of the liens granted to Agent under the
Collateral Documents with respect to the 454 Collateral, including
the Credit Agreement and the Mortgage.

 

(b) Borrower shall
cause the proceeds of the sale of the 454 Collateral in the amount
of $975,000 (the “454 Sale Proceeds”) to be
deposited into the Restricted Account. Borrower hereby acknowledges
and agrees that the 454 Sale Proceeds and any and all funds in the
Restricted Account shall be subject to Agent’s security
interest, shall constitute Collateral for the Obligations and shall
be subject to the terms hereof and the terms of the Credit
Agreement (including Section 2.11 thereof
(Application of Payments)) and of the Forbearance
Agreement.

 

(c) Effective upon
Agent’s receipt of a wire transfer confirmation number
evidencing the transfer of the 454 Sale Proceeds as described in
Section 7(b) above
and Agent’s confirmation of receipt of such funds, and
provided no Forbearance Termination Event then exists, Agent agrees
to release and discharge its security interests and liens in the
454 Collateral and authorizes and consents to any filings necessary
to evidence the releases pursuant to this Section 7 or the discharge of
any liens thereof.

 

8. Disbursements. Provided no
Forbearance Termination Event then exists, the Lenders hereby
approve Borrower’s Cash Flow Budget prepared on December 9,
2019 for the limited purpose of making disbursements from available
funds in the Restricted Account to fund Borrower’s Liquidity
Needs identified in such Cash Flow Budget through the week ending
December 13th and authorize Agent
to make such disbursements. Notwithstanding the foregoing approval
of such Cash Flow Budget, to the extent future disbursements from
the Restricted Account are requested after December 13, 2019,
Borrower must obtain the approval of the Lenders of a new Cash Flow
Budget as set forth in Section 5(g) of the Forbearance
Agreement (as amended hereby) that references the applicable
provisions of the Second Amendment.

 

9. Representations and Warranties.
Each of Borrower and Guarantors represents and warrants that (a)
after giving effect to this Amendment, except for the
representations and warranties which are made only as of a prior
date, the representations and warranties set forth in the Credit
Agreement and in the other Loan Documents are true and correct in
all respects as of the Amendment Effective Date, as if made on and
as of such date; (b) after giving effect to this Amendment, no
Default or Event of Default has occurred and is continuing (other
than the Specified Defaults, as such term is amended hereby); (c)
the execution, delivery and performance of this Amendment are
within the corporate power and authority of such Person and have
been duly authorized by appropriate corporate action and
proceedings; (d) this Amendment constitutes a legal, valid,
and binding obligation of such Person enforceable in accordance
with its terms, except as limited by applicable bankruptcy,
insolvency, reorganization, moratorium, or similar laws affecting
the rights of creditors generally and general principles of equity;
(e) there are no governmental or other third party consents,
licenses and approvals required in connection with the execution,
delivery, performance, validity and enforceability of this
Amendment; and (f) the Liens under the Loan Documents are valid and
subsisting and secure Borrower’s and such Person’s
obligations under the Loan Documents.

 

10. Conditions Precedent. This
Amendment shall become effective on the date (the
“Amendment Effective
Date”) each of the following conditions shall have
been satisfied or waived by Agent in its sole
discretion:

 

(a) This Amendment. Agent shall
have received this Amendment, duly executed by Borrower, Guarantors
and the Lenders.

 

(b) No Default. Upon giving effect
to this Amendment, there shall be no Default or Event of Default
(other than the Specified Defaults as such term is amended
hereby).

 

(c) Representations and Warranties.
The representations and warranties in this Amendment shall be true
and correct in all material respects.

 

(d) Prior Amendment Fee. Agent
shall have received the fee due pursuant to the First Amendment in
the amount of $225,000 in accordance with Section 7
thereof.

 

11. Forbearance Extension Fee. In
consideration for the agreement of Lenders to enter into this
Amendment, Borrower shall pay to Agent for the account of the
Lenders a forbearance amendment fee in the amount of 100 basis
points of the outstanding principal amount of the Loans (the
“Amendment
Fee”), which Amendment Fee shall be deemed fully
earned and non-refundable for any reason whatsoever and shall be
due and payable on December 16, 2019 after giving effect to
the rollover of the LIBOR Loan due on such Payment Date. In lieu of
cash payment, the Amendment Fee may be paid in kind by capitalizing
the amount thereof and adding it to the principal amount of the
Loans, whereby the principal amount of each outstanding LIBOR Loan
shall thereafter increase by 100 basis points and such increase
shall become part of the principal amount of such LIBOR Loan and
bear interest in accordance with the Credit Agreement for all
purposes.

 

12. General Release. Each of
Borrower and Guarantors, on behalf of itself and on behalf of its
Subsidiaries, successors, assigns, legal representatives and
financial advisors (collectively, the “Releasing Parties”),
hereby releases, acquits and forever discharges Agent, the Lenders
and each of their respective past and present directors, officers,
employees, agents, attorneys, affiliates, predecessors, successors,
administrators and assigns (the “Released Parties”) of and
from any and all claims, actions, causes of action, demands,
rights, damages, costs, loss of service, expenses and compensation
whatsoever heretofore or hereafter arising from any events or
occurrences, or anything done, omitted to be done, or allowed to be
done by any of the Released Parties, on or before the date of
execution of this Amendment, WHETHER KNOWN OR UNKNOWN, FORESEEN OR
UNFORESEEN, including, without limitation, any of the same arising
from or related to anything done, omitted to be done, or allowed to
be done by any of the Released Parties and in any way connected
with this Amendment, the Forbearance Agreement, or any of the Loan
Documents, any other credit facilities provided or not provided,
any advances made or not made, or any past or present deposit or
other accounts of any Releasing Party with any Released Party and
the handling of the same by any Released Party, including, without
limitation, the manner and timing in which items were deposited or
credited thereto or funds transferred therefrom or made available
to any of the Releasing Parties, the honoring or returning of any
checks drawn on any account, and any other dealings between the
Releasing Parties and the Released Parties (the “Released Matters”).
Releasing Parties each further agree never to commence, aid or
participate in (except to the extent required by order or legal
process issued by a court or governmental agency of competent
jurisdiction) any legal action or other proceeding based in whole
or in part upon the Released Matters. In furtherance of this
general release, Releasing Parties each acknowledge and waive the
benefits of California Civil Code Section 1542 (and all similar
ordinances and statutory, regulatory, or judicially created laws or
rules of any other jurisdiction), which provides:

 

A
GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR
RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER
FAVOR AT THE TIME OF EXECUTING THE RELEASE, AND THAT IF KNOWN BY
HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT
WITH THE DEBTOR OR RELEASED PARTY.

 

Releasing Parties
each agree that this waiver and release is an essential and
material of this Amendment, and that the agreements in this
paragraph are intended to be in full satisfaction of any alleged
injuries or damages to or of any Releasing Parties in connection
with the Released Matters. Each Releasing Party represents and
warrants that it has not purported to convey, transfer or assign
any right, title or interest in any Released Matter to any other
person or entity and that the foregoing constitutes a full and
complete release of the Released Matters. Releasing Parties each
also understand that this release shall apply to all unknown or
unanticipated results of the transactions and occurrences described
above, as well as those known and anticipated. Releasing Parties
each have consulted with legal counsel prior to signing this
release, or had an opportunity to obtain such counsel and knowingly
chose not to do so, and each Releasing Party executes such release
voluntarily, with the intention of fully and finally extinguishing
all Released Matters.

 

13. Miscellaneous.

 

(a) Breach as Event of Default; Agreement
as Loan Document. It shall be an immediate Event of Default
under the Credit Agreement if Obligor breaches any covenant
contained herein or in the Forbearance Agreement (as amended
hereby) or if any representation or warranty contained herein or in
the Forbearance Agreement (as amended hereby) proves to be
inaccurate or untrue in any material respect. Each of the Loan
Documents shall be deemed modified so far as to be consistent with
this Amendment. Except as specifically modified and amended herein,
all of the terms, covenants, conditions and agreements contained in
the Credit Agreement and the other Loan Documents shall remain in
full force and effect. In the event of any inconsistency between
this Amendment and any Loan Document, the provisions of this
Amendment shall control. This Amendment and the Forbearance
Agreement (as amended hereby) shall each constitute a Loan Document
under the Credit Agreement. Any provision of any Loan Document
which applies to Loan Documents generally shall apply to this
Amendment and the Forbearance Agreement (as amended
hereby).

 

(b) Review And Construction Of
Documents. Each party hereto hereby acknowledges, and
represents and warrants to the other parties hereto,
that:

 

(i) it has had the
opportunity to consult with legal counsel of its own choice and has
been afforded an opportunity to review this Amendment and the
Forbearance Agreement (as amended by this Amendment) with legal
counsel;

 

(ii) it
has carefully reviewed this Amendment and the Forbearance Agreement
(as amended by this Amendment) and fully understands all terms and
provisions of this Amendment and the Forbearance Agreement (as
amended by this Amendment);

 

(iii) it
has freely, voluntarily, knowingly, and intelligently entered into
this Amendment and the Forbearance Agreement (as amended by this
Amendment) of its own free will and volition;

 

(iv) none
of the Lenders or Agent have a fiduciary relationship with any
Obligor and the Obligor does not have a fiduciary relationship with
Agent or the Lenders, and the relationship between the Lenders or
Agent, on the one hand, and Obligor, on the other hand, is solely
that of creditor and debtor; and

 

(v) no joint venture
exists among Obligor and the Lenders or Agent.

 

(c) Severability. Any provision of
this Amendment held by a court of competent jurisdiction to be
invalid or unenforceable shall not impair or invalidate the
remainder of this Amendment, and the effect thereof shall be
confined to the provision so held to be invalid or
unenforceable.

 

(d) APPLICABLE LAW. THIS AMENDMENT,
AND THE RIGHTS AND OBLIGATIONS OF THE PARTIES HERETO, SHALL BE
GOVERNED BY, AND SHALL BE CONSTRUED AND INTERPRETED IN ACCORDANCE
WITH, THE LAWS OF THE STATE OF NEW YORK.

 

(e) WAIVER OF JURY TRIAL. EACH
PARTY HERETO HEREBY IRREVOCABLY AND UNCONDITIONALLY WAIVES TRIAL BY
JURY IN ANY LEGAL ACTION OR PROCEEDING RELATING TO THIS AMENDMENT,
THE FORBEARANCE AGREEMENT (AS AMENDED BY THIS AMENDMENT) OR ANY
OTHER LOAN DOCUMENT AND FOR ANY COUNTERCLAIM THEREIN.

 

(f) Successors and Assigns. This
Amendment is binding upon and shall inure to the benefit of Agent,
Lenders and Obligor and their respective successors and assigns;
provided,
however, that
Obligor may not assign or transfer any of its rights or obligations
hereunder without the prior written consent of Agent and Lenders.
The execution and delivery of this Amendment by any Lender prior to
the Amendment Effective Date shall be binding upon its successors
and assigns and shall be effective as to any Loans or Revolving
Commitment assigned to such Lender after such execution and
delivery.

 

(g) Counterparts. This Amendment
may be executed in one or more counterparts, each of which when so
executed shall be deemed to be an original, but all of which when
taken together shall constitute one and the same instrument. An
executed signature page of this Amendment may be delivered by
facsimile transmission or electronic PDF of the relevant signature
page hereof.

 

(h) Headings. The headings,
captions and arrangements used in this Amendment are for
convenience only and shall not affect the interpretation of this
Amendment.

 

(i) Expenses of Agent and Lenders.
Borrower shall promptly pay all fees, costs, charges, expenses, and
disbursements of Agent incurred in connection with the preparation,
execution, and delivery of this Amendment, and the other documents
contemplated by this Amendment, including all legal fees and
expenses.

 

(j) Further Assurances. Obligor
agrees to execute, acknowledge, deliver, file and record such
further certificates, instruments and documents, and to do all
other acts and things, as may be reasonably requested by Agent and
necessary or reasonably advisable to carry out the intents and
purposes of this Amendment.

 

(k) Amendments. The provisions of
the Forbearance Agreement (as amended by this Amendment) may be
further amended or waived by an instrument in writing signed by
Borrower, the Lenders and Agent, provided that an amendment
limited to extending the Forbearance Period shall be effective
pursuant to a writing signed by Agent, at the direction of the
Requisite Lenders, and Borrower.

 

(l) Integration; No Oral
Agreements. This Amendment, the Forbearance Agreement (as
amended), the Credit Agreement, the other Loan Documents and the
other written agreements, instruments, and documents entered into
in connection therewith set forth in full the terms of agreement
between the parties hereto and thereto with respect to the subject
matter thereof and are intended as the full, complete, and
exclusive contracts governing the relationship between such parties
with respect to the subject matter thereof, superseding all other
discussions, promises, representations, warranties, agreements, and
understandings between the parties with respect thereto. There are
no oral agreements among the parties hereto.

 

(m) THIS AMENDMENT AND
THE FORBEARANCE AGREEMENT (AS AMENDED) EMBODY THE FINAL, ENTIRE
AGREEMENT AMONG THE PARTIES HERETO REGARDING THE CREDIT
PARTIES’ FORBEARANCE WITH RESPECT TO THEIR RIGHTS AND
REMEDIES WHICH MAY ARISE AS A RESULT OF THE SPECIFIED EVENTS OF
DEFAULT AND SUPERSEDES ANY AND ALL PRIOR COMMITMENTS, AGREEMENTS,
REPRESENTATIONS, AND UNDERSTANDINGS, WHETHER WRITTEN OR ORAL,
RELATING TO THE SUBJECT MATTER HEREOF AND MAY NOT BE CONTRADICTED
OR VARIED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL
AGREEMENTS OR DISCUSSION OF THE PARTIES HERETO. THERE ARE NO ORAL
AGREEMENTS AMONG THE PARTIES HERETO.

	
	

	
 

	
 

	
 

	

-

 

 

IN
WITNESS WHEREOF, the parties have entered into this Amendment by
their respective duly authorized officers as of the date first
above written.

 

BORROWER:

 

AEROCENTURY
CORP.,

a
Delaware corporation

 

 

By:            

_________________________

Name:
_________________________

Title:                       

_________________________

 

 

 

 

GUARANTORS:

 

JETLEET
HOLDING CORP.,

a
California corporation

 

 

By:            

_________________________

Name:
_________________________

Title:                       

_________________________

 

 

 

JETFLEET MANAGEMENT
CORP.,

a
California corporation

 

 

By:            

_________________________

Name:
_________________________

Title:                       

_________________________

 

 

	

	

	
 

	
 

	
 

	

-

 

 

ADMINISTRATIVE
AGENT AND LENDER:

 

 

MUFG
UNION BANK, N.A.

 

By:            

_________________________

 

Name:
_________________________

 

Title:                       

_________________________

 

 

 

 

	

	

	
 

	
 

	
 

	

-

 

 

MUFG LTD:

 

MUFG
BANK, LTD.

 

By:            

_________________________

 

Name:
_________________________

 

Title:                       

_________________________

 

	

	

	
 

	
 

	
 

	

-

 

 

LENDER:

 

UMPQUA
BANK

 

By:            

_________________________

Name:
_________________________

Title:                       

_________________________

 

 

	

	

S-7

	
 

	
 

	
 

	

-

 

 

LENDER:

 

ZIONS
BANCORPORATION, N.A. (fka ZB, N.A.) dba CALIFORNIA BANK AND
TRUST

 

By:            

_________________________

Name:
_________________________

Title:                       

_________________________

 

 

 

 

	

	

	
 

	
 

	
 

	

-

 

 

LENDER:

 

U.S.
BANK NATIONAL ASSOCIATION

 

By:            

_________________________

Name:
_________________________

Title:                       

_________________________

 

 

 

 

 

	
	

	
 

	
 

	
 

	

-

 

 

LENDER:

 

COLUMBIA STATE
BANK

 

By:            

_________________________

Name:
_________________________

Title:                       

_________________________

 

 

 

 

	

	

	
 

	
 

	
 

	

-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00302-of-00352.parquet"}]]